Rapid Diagnostic Technology for AUGIB Based on Analysis of VOCs in Exhaled Breath

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBeijing 302 Hospital

About this trial

This study aims to develop a non-invasive and rapid diagnostic technology for acute upper gastrointestinal bleeding (AUGIB) by analyzing volatile organic compounds (VOCs) in exhaled breath. Clinically confirmed patients will be divided into three groups (no bleeding, minor bleeding, major bleeding) based on endoscopic findings. VOC profiles will be analyzed to construct a predictive model, validated for sensitivity and specificity (both targets ≥0.7). This approach addresses the limitations of endoscopy in emergency or resource-limited settings, improving diagnostic efficiency and reducing mortality.

Eligibility criteria

Qualifiers

Age ≥18 years;

Clinical suspicion of AUGIB (e.g., hematemesis, melena);

Fasting ≥4 hours;

Signed informed consent.

Disqualifiers

Severe pulmonary dysfunction or recent lung infection (within 1 week);

Cardiac/renal failure or disseminated intravascular coagulation;

Contraindications to endoscopy;

High-risk conditions (e.g., massive ascites);

Trial design

Treatments tested in this trial

  • Gastroscopy
  • Gas Chromatography - Mass Spectrometry

Treatment groups

200 Participants
are divided into 3 treatment groups

Locations

This trial has no locations

Sponsors and collaborators